Supplementary Tables 1-3 from A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial